References
- Maloney D G, Grillo-Lopez A J, White C A, Bodkin D, Schilder R J, Neidhart J A, Janakiraman N, Foon K A, Liles T M, Dallaire B K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195
- Bosly A, Keating M J, Stasi R, Bradstock K. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma. Anticancer Drugs 2002; 13(Suppl 2)S25–S33
- Aksoy S, Harputluoglu H, Kilickap K, Dede D, Dizdar O, Altundag K, Barista I. Rituximab induced viral infections in lymphoma patients. Leukemia and Lymphoma 2007; 48: 1307–1312
- Lok A S, Liang R H, Chiu E K, Wong K L, Chan T K, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182–188
- Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699–712
- Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391–396
- Law J K, Ho J K, Hoskins P J, Erb S R, Steinbrecher U P, Yoshida E M. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085–1089
- Kaplan L D, Lee J Y, Ambinder R F, Sparano J A, Cesarman E, Chadburn A, Levine A M, Scadden D T. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106: 1538–1543
- Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 38: 433–436
- Solal-Celigny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res 2006; 30(Suppl 1)S16–S21
- Hurvitz S A, Timmerman J M. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol 2005; 17: 432–440